RxDoctor Payments Data

George Dekeles, APRN

Psychiatric/Mental Health · St Petersburg, FLNPI 1477855872

Payments from drug & device makers

$1,354in general payments, 2019–2025

Across 29 payments — averaging $46.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$403
  • Johnson & Johnson$285
  • Neurocrine Biosciences, Inc.$259
  • Alkermes, Inc.$214
  • AbbVie$65
  • Otsuka America Pharmaceutical, Inc.$61
  • plus $66 from 2 others

What the payments were for

  • Food & beverage$1,23291%
  • Education$1229%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,354 in reported general payments places this provider in the 65th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$37,471
Medicare patients
80
Services billed
514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole12$24,358
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$3,068
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine77$1,766
Quetiapine Fumarate108$1,441
Alprazolam293$963
Mirtazapine44$954
Bupropion XlBupropion Hcl63$943
Trazodone Hcl73$878
Duloxetine Hcl43$848
Buspirone Hcl50$704
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$693
Clonazepam146$623
Venlafaxine Hcl ErVenlafaxine Hcl25$558
Aripiprazole23$552
Methylphenidate Hcl17$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$61$24,35812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →